{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:07:13Z","timestamp":1789236433911,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bpg.2025.101992","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:19:44Z","timestamp":1739819984000},"page":"101992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Biobetters and biosimilars in inflammatory bowel disease"],"prefix":"10.1016","volume":"77","author":[{"given":"Jacopo","family":"Fanizza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Faggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Allocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Furfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso Lorenzo","family":"Parigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Cicerone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Andres","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1198-6121","authenticated-orcid":false,"given":"Ferdinando","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10080","key":"10.1016\/j.bpg.2025.101992_bib1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bpg.2025.101992_bib2","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3390\/biomedicines11082139","article-title":"New technologies in digestive endoscopy for ulcerative colitis patients","volume":"11","author":"Biamonte","year":"2023","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.bpg.2025.101992_bib3","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The burden of inflammatory bowel disease in Europe in 2020","volume":"15","author":"Zhao","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.bpg.2025.101992_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MOG.0000000000000361","article-title":"Surgical rates in the era of biological therapy: up, down or unchanged?","volume":"33","author":"Olivera","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"issue":"9","key":"10.1016\/j.bpg.2025.101992_bib5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.14309\/ajg.0000000000002345","article-title":"A narrative review of financial burden, distress, and toxicity of inflammatory bowel diseases in the United States","volume":"118","author":"Kahn-Boesel","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.bpg.2025.101992_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/1744666X.2023.2292768","article-title":"Management and treatment optimization of patients with mild to moderate ulcerative colitis","volume":"20","author":"D'Amico","year":"2024","journal-title":"Expet Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14712598.2020.1811849","article-title":"Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13","volume":"21","author":"Parigi","year":"2021","journal-title":"Expet Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.bpg.2025.101992_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","article-title":"Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study","volume":"5","author":"Burisch","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2025.101992_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","article-title":"The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases","volume":"80","author":"Kim","year":"2020","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bpg.2025.101992_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11894-023-00913-5","article-title":"Biosimilars in IBD: what every clinician needs to know","volume":"26","author":"Angyal","year":"2024","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrgastro.2016.155","article-title":"Biosimilars in IBD: from theory to practice","volume":"14","author":"Danese","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2025.101992_bib13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5639\/gabij.2014.0304.039","article-title":"Biosimilars versus \u2018biobetters\u2019\u2014a regulator's perspective","volume":"3","author":"Anour","year":"2014","journal-title":"Generics Biosimilars Initiat J"},{"issue":"12","key":"10.1016\/j.bpg.2025.101992_bib15","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","article-title":"Biosimilars in inflammatory bowel disease: facts and fears of extrapolation","volume":"14","author":"Ben-Horin","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101992_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.dld.2019.02.004","article-title":"Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","volume":"51","author":"Fiorino","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2025.101992_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2147\/BTT.S124476","article-title":"Biosimilars and the extrapolation of indications for inflammatory conditions","volume":"11","author":"Tesser","year":"2017","journal-title":"Biol Targets & Ther"},{"issue":"4","key":"10.1016\/j.bpg.2025.101992_bib18","first-page":"3","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Rand Health Q"},{"key":"10.1016\/j.bpg.2025.101992_bib19","unstructured":"Biosimilars overview for health care professionals. [Internet]. U.S. Food & Drug Administration. Updated March 1, 2023. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/overview-health-care-professionals."},{"key":"10.1016\/j.bpg.2025.101992_bib20","article-title":"NF-\u03baB inducing kinase regulates intestinal immunity and homeostasis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.bpg.2025.101992_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.101992_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues","volume":"14","author":"Peyrin-Biroulet","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study","volume":"63","author":"Van Der Valk","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2025.101992_bib24","unstructured":"Inflectra. European Medicines Agency [Internet]. [cited 2020 May 24]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inflectra."},{"issue":"10","key":"10.1016\/j.bpg.2025.101992_bib25","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.bpg.2025.101992_bib26","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101992_bib27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101992_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101992_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MIB.0000000000000995","article-title":"The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar","volume":"23","author":"Fiorino","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"10182","key":"10.1016\/j.bpg.2025.101992_bib30","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bpg.2025.101992_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7326\/M18-1512","article-title":"Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study","volume":"170","author":"Meyer","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10086","key":"10.1016\/j.bpg.2025.101992_bib32","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bpg.2025.101992_bib33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/joim.12880","article-title":"Long\u2010term efficacy and safety of biosimilar infliximab (CT\u2010P13) after switching from originator infliximab: open\u2010label extension of the NOR\u2010SWITCH trial","volume":"285","author":"Goll","year":"2019","journal-title":"J Intern Med"},{"issue":"11","key":"10.1016\/j.bpg.2025.101992_bib34","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/MIB.0000000000001237","article-title":"Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort","volume":"23","author":"Gonczi","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101992_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40259-015-0150-5","article-title":"A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade\u00ae) in healthy subjects","volume":"29","author":"Shin","year":"2015","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","article-title":"A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Choe","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101992_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ibd\/izaa036","article-title":"The SPOSIB SB2 Sicilian cohort: safety and effectiveness of infliximab biosimilar SB2 in inflammatory bowel diseases, including multiple switches","volume":"27","author":"Macaluso","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2025.101992_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211023384","article-title":"Switching from infliximab originator to SB2 biosimilar in inflammatory bowel diseases: a multicentric prospective real-life study","volume":"14","author":"Massimi","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101992_bib39","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/apt.16497","article-title":"An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch","volume":"54","author":"Luber","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2025.101992_bib40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ibd\/izab099","article-title":"Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study","volume":"28","author":"Hanzel","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-018-1646-4","article-title":"A randomized controlled trial comparing PF-06438179\/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy","volume":"20","author":"Cohen","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bpg.2025.101992_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000002408","article-title":"Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease","author":"Dipasquale","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2025.101992_bib43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.dld.2022.12.008","article-title":"Switching from SB2 to PF-06438179\/GP1111 and back in inflammatory bowel disease: \u201cThe Superswitchers.\u201d","volume":"55","author":"Macaluso","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2025.101992_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1424606","article-title":"Anti-TNF\u03b1 in inflammatory bowel disease: from originators to biosimilars","volume":"15","author":"Zeng","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.bpg.2025.101992_bib45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2015-208914","article-title":"A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab","volume":"76","author":"Kaur","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.bpg.2025.101992_bib46","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","article-title":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101992_bib47","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","article-title":"Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study","volume":"76","author":"Papp","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bpg.2025.101992_bib48","article-title":"Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohns disease: an observational study","author":"Ribaldone","year":"2020","journal-title":"Rev Esp Enferm Dig"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/apt.17525","article-title":"Real\u2010world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: the ADA\u2010SWITCH study","volume":"58","author":"Casanova","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/art.40336","article-title":"Phase III randomized study of SB 5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate\u2010to\u2010severe rheumatoid arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.bpg.2025.101992_bib51","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/ecco-jcc\/jjaa001","article-title":"Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: short-term experience from a single tertiary clinical centre","volume":"14","author":"Lukas","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.101992_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211031420","article-title":"A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study","volume":"14","author":"Barberio","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"issue":"15","key":"10.1016\/j.bpg.2025.101992_bib53","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.3390\/jcm10153387","article-title":"Switching from biosimilar to biosimilar adalimumab, including multiple switching, in Crohn's disease: a prospective study","volume":"10","author":"Ribaldone","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.bpg.2025.101992_bib54","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/13543784.2016.1255724","article-title":"Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE\u00ae-PK) in healthy subjects","volume":"25","author":"Wynne","year":"2016","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.bpg.2025.101992_bib55","article-title":"Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study","volume":"7","author":"Cohen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.bpg.2025.101992_bib56","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2468-1253(21)00252-1","article-title":"Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial","volume":"6","author":"Hanauer","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2025.101992_bib57","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.bpg.2025.101992_bib58","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40259-020-00447-6","article-title":"Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study","volume":"34","author":"Wiland","year":"2020","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.bpg.2025.101992_bib59","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3390\/biomedicines10081799","article-title":"Adalimumab biosimilar GP2017 versus adalimumab originator in treating patients with inflammatory bowel diseases: a real-life, multicenter, observational study","volume":"10","author":"Mocci","year":"2022","journal-title":"Biomedicines"},{"issue":"21","key":"10.1016\/j.bpg.2025.101992_bib60","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.3390\/jcm12216839","article-title":"Efficacy and safety of adalimumab biosimilar GP2017 in patients with inflammatory bowel disease","volume":"12","author":"Vernero","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.bpg.2025.101992_bib61","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ibd\/izac092","article-title":"Comparison of performances of adalimumab biosimilars SB5, ABP501, GP2017, and MSB11022 in treating patients with inflammatory bowel diseases: a real-life, multicenter, observational study","volume":"29","author":"Tursi","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.bpg.2025.101992_bib62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.15403\/jgld-4608","article-title":"Replacement of adalimumab originator to adalimumab biosimilar for a non-medical reason in patients with inflammatory bowel disease: a real-life comparison of adalimumab biosimilars currently available in Italy","volume":"31","author":"Tursi","year":"2022","journal-title":"J Gastrointestin Liver Dis"},{"issue":"5","key":"10.1016\/j.bpg.2025.101992_bib63","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3390\/jcm13051519","article-title":"Ustekinumab in the treatment of inflammatory bowel diseases: evolving paradigms","volume":"13","author":"Mocci","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.bpg.2025.101992_bib64","year":"2018"},{"issue":"4","key":"10.1016\/j.bpg.2025.101992_bib65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40268-023-00441-7","article-title":"Analytical and functional similarity of the biosimilar candidate ABP 654 to ustekinumab reference product","volume":"23","author":"Cantin","year":"2023","journal-title":"Drugs R&D"},{"issue":"9","key":"10.1016\/j.bpg.2025.101992_bib66","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cpdd.1301","article-title":"Pharmacokinetic similarity of ABP 654, an ustekinumab biosimilar candidate: results from a randomized, double\u2010blind study in healthy subjects","volume":"12","author":"Chow","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.bpg.2025.101992_bib67","author":"Amgen"},{"key":"10.1016\/j.bpg.2025.101992_bib68","author":"Amgen"},{"issue":"5","key":"10.1016\/j.bpg.2025.101992_bib69","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/13543784.2023.2215426","article-title":"A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults","volume":"32","author":"Wynne","year":"2023","journal-title":"Expet Opin Invest Drugs"},{"issue":"5","key":"10.1016\/j.bpg.2025.101992_bib70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5414\/CP204492","article-title":"Comparison of SB17 and reference ustekinumab in healthy adults: a randomized, double-blind, single-dose, phase I study","volume":"62","author":"Jeong","year":"2024","journal-title":"Int J Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.bpg.2025.101992_bib71","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/14712598.2023.2235263","article-title":"Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis","volume":"23","author":"Feldman","year":"2023","journal-title":"Expet Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2025.101992_bib72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2024.04.045","article-title":"A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis","volume":"91","author":"Feldman","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bpg.2025.101992_bib73","author":"Celltrion"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","article-title":"Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase III study","volume":"38","author":"Papp","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.bpg.2025.101992_bib75","author":"Carmona-Rocha"},{"issue":"4","key":"10.1016\/j.bpg.2025.101992_bib76","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/eci.10.40","article-title":"Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease","volume":"6","author":"Fiorino","year":"2010","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.bpg.2025.101992_bib78","unstructured":"Polpharma looks to challenge Takeda's Entyvio in IBD [Internet]. [cited 2024 Oct 20]. Available from: https:\/\/www.clinicaltrialsarena.com\/news\/polpharma-looks-to-challenge-takedas-entyvio-in-ibd\/."},{"key":"10.1016\/j.bpg.2025.101992_bib79","unstructured":"Polpharma Biologics S.A. A Randomized, Double-blind, Multicenter Phase 3 Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) to Compare the Efficacy, Safety and Immunogenicity of PB016 and Entyvio\u00ae for the Induction and Maintenance of Clinical Response and Remission [Internet]. clinicaltrials.gov; 2024 Jul [cited 2024 Oct 20]. Report No.: NCT05771155. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05771155."},{"issue":"7","key":"10.1016\/j.bpg.2025.101992_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102849","article-title":"Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus","volume":"20","author":"D'Amico","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.bpg.2025.101992_bib81","series-title":"Generic and hybrid medicines","year":"2012"},{"key":"10.1016\/j.bpg.2025.101992_bib82","series-title":"Interpretation of the \u201cdeemed to be a license\u201d provision of the biologics price competition and innovation act of 2009 [internet]","year":"2020"},{"issue":"5","key":"10.1016\/j.bpg.2025.101992_bib83","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","article-title":"Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial","volume":"60","author":"Westhovens","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"issue":"Supplement_1","key":"10.1016\/j.bpg.2025.101992_bib84","doi-asserted-by":"crossref","first-page":"S066","DOI":"10.1093\/ecco-jcc\/jjy222.096","article-title":"DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn's disease","volume":"13","author":"Reinisch","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.bpg.2025.101992_bib85","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2025.101992_bib86","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2025.101992_bib87","series-title":"Tolerability and pharmacokinetics (PK) of RT-111- RaniPill capsule containing ustekinumab - administered orally to healthy volunteers","article-title":"A phase 1 study to evaluate the safety","year":"2024"},{"issue":"3","key":"10.1016\/j.bpg.2025.101992_bib88","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of Vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous Vedolizumab in patients with moderately to severely active Crohn's disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib90","article-title":"S0653 long-term treatment with Vedolizumab SC in ulcerative colitis: interim results from VISIBLE OLE","volume":"115","author":"Vermeire","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2025.101992_bib91","first-page":"360","article-title":"Practical primer addressing real-world use scenarios of subcutaneous Vedolizumab in ulcerative colitis and Crohn's disease: post hoc analyses of VISIBLE studies","volume":"5","author":"Sandborn","year":"2023","journal-title":"Crohns Colitis"},{"issue":"5","key":"10.1016\/j.bpg.2025.101992_bib92","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.bpg.2025.101992_bib93","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3390\/jcm13113069","article-title":"Benefits of biosimilars in the management of patients with inflammatory bowel disease: an international survey","volume":"13","author":"D'Amico","year":"2024","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.bpg.2025.101992_bib94","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","article-title":"Biosimilars: the science of extrapolation","volume":"124","author":"Weise","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bpg.2025.101992_bib95","article-title":"Current evidence for combined targeted therapy for the treatment of inflammatory bowel disease","volume":"26","author":"Wetwittayakhlang","year":"2023","journal-title":"J Can Assoc Gastroenterol."},{"issue":"12","key":"10.1016\/j.bpg.2025.101992_bib96","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","article-title":"Nocebos in rheumatology: emerging concepts and their implications for clinical practice","volume":"14","author":"Kravvariti","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101992_bib97","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14712598.2020.1817374","article-title":"Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?","volume":"21","author":"D'Amico","year":"2021","journal-title":"Expet Opin Biol Ther"},{"issue":"9","key":"10.1016\/j.bpg.2025.101992_bib98","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/1744666X.2018.1512406","article-title":"The nocebo effect: a clinical challenge in the era of biosimilars","volume":"14","author":"Pouillon","year":"2018","journal-title":"Expet Rev Clin Immunol"},{"issue":"7","key":"10.1016\/j.bpg.2025.101992_bib99","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/ecco-jcc\/jjy020","article-title":"Second N-ecco consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis","volume":"12","author":"Kemp","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101992_bib100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.dld.2019.11.004","article-title":"Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: results of a workshop from the NOCE-BIO consensus group","volume":"52","author":"D'Amico","year":"2020","journal-title":"Dig Liver Dis"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T07:38:26Z","timestamp":1754293106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691825000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":98,"alternative-id":["S1521691825000198"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2025.101992","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biobetters and biosimilars in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2025.101992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101992"}}